Nvidia’s Blowout Earnings & Stock Split + Britain’s Damaged Economy
Prof G Markets
00:00
Pricing Dilemmas and Investment Critiques
This chapter explores the pricing and regulatory challenges of a new GLP-1 drug that offers a cost-effective alternative without FDA approval, raising questions about its market sustainability. Additionally, the discussion critiques Vivek's investment in BuzzFeed and transitions into a commentary on NVIDIA's earnings, coupled with a promotional mention for a venture capital platform.
Transcript
Play full episode
